#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
This is one of the largest studies ever conducted on teen cannabis use and psychiatric outcomes, and it reinforces that age restrictions and youth prevention should be central to any legalization framework.
A JAMA Health Forum study of 463,396 adolescents ages 13 to 17 found cannabis use was linked to a twofold increase in psychotic and bipolar disorder risk by age 26. The study represents one of the largest longitudinal investigations of this association, drawing on clinical health records rather than self-reported data. Researchers note that the findings reinforce the need for youth-focused prevention strategies regardless of the broader legalization debate.
“This study doesn’t argue against legalization,it argues for honest, evidence-based youth prevention as a non-negotiable component of any responsible cannabis policy.”
A landmark JAMA Health Forum study tracking nearly half a million adolescents reveals a twofold increased risk of psychotic and bipolar disorders among cannabis users by age 26. Drawing on actual clinical records rather than self-reported data, this longitudinal research offers compelling evidence for conversations about adolescent neurodevelopment and substance use.
Have thoughts on this? Share it:
For readers who would like a deeper examination of the study’s methodology, statistical framing, and what these findings do and do not establish clinically, Dr Caplan has published a detailed clinical review of the original JAMA Health Forum paper here: Adolescent Cannabis Use and Psychosis Risk – Study Review.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
